Anavex Life Sciences Corp (AVXL)

[nidan7500]

Bear also consider the PR today from BIIB on their most recent trial failure for a stroke treatment...using MS drug.OOOOOPS, Never Mind. I would like to believe we will all look back of this example and shiver like we do when we see photos of civil war operating room practices. "what were they thinking?"

Can we take the following as an example of "Never Again"?. Will ALL BP ex. BIIB be forced to reconsider their practices? Will the FDA learn how to play hardball when the next trial is presented (before guidance on Precision medicine) are published. Is AVXL really a beta site for new trails or are they on their own? Clearly, once the new FDA/Dr.M. trials protocols are adapted, there will be no going back. The future of the AVXL investment will be driven by the acceptance of RWE and early trials actions to approve uses. Could this explode when investors understand or will that take years also?
https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM592001.pdf

Keeping my fingers crossed but have limited insight into just how fast the BP/WS crowd will buy in, or IF they will at all. They have to choose. Keep spending massive amounts of money and getting high risk lousy results or "STOP THE TRAIN" and reinvest in new science/technology/AI/other. These are the kinds of choices that companies make to either survive or disappear. Many, many examples to point to. The rest of the world has begun to understand that .."It's ALL about risk. Understanding RISK and limiting/mitigating it. or die.

From PR by BIIB:

Feb 7 (Reuters) - Biogen Inc said on Wednesday it would stop developing its multiple sclerosis drug Tysabri to treat patients with acute ischemic stroke after it failed a mid-stage study.
The treatment did not improve patients' self-dependence and their ability to perform daily activities when compared with a placebo, the drugmaker said.
Ischemic strokes require immediate medical attention and occur when blood supply is cut off to part of the brain.
Analysts have called Biogen's move to develop Tysabri for ischemic strokes as "high risk."
"Stroke is very challenging and even if it works, (Wall Street) may be hesitant to ascribe too much value as Biogen would need to run a larger trial and the commercial opportunity is still far off," Jefferies analyst Michael Yee said last month.